A Phase I Study of Single Subcutaneous Dose of SHR-1894 in Healthy Subjects

NCT07414602 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

40

Enrollment

INDUSTRY

Sponsor class

Conditions

Dermatitis

Interventions

DRUG: SHR-1894 Injection
DRUG: SHR-1894 Injection Placebo

Sponsor

Suzhou Suncadia Biopharmaceuticals Co., Ltd.